company background image
VINEETLAB logo

Vineet Laboratories NSEI:VINEETLAB Stock Report

Last Price

₹55.30

Market Cap

₹509.8m

7D

-10.3%

1Y

8.9%

Updated

23 Jul, 2024

Data

Company Financials

Vineet Laboratories Limited

NSEI:VINEETLAB Stock Report

Market Cap: ₹509.8m

VINEETLAB Stock Overview

Engages in the research, development, manufacture, and sale of active pharmaceutical ingredients and fine chemicals in India.

VINEETLAB fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance3/6
Financial Health2/6
Dividends0/6

Vineet Laboratories Limited Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Vineet Laboratories
Historical stock prices
Current Share Price₹55.30
52 Week High₹88.90
52 Week Low₹46.60
Beta-0.27
11 Month Change-11.59%
3 Month Change3.17%
1 Year Change8.86%
33 Year Change-49.06%
5 Year Changen/a
Change since IPO19.70%

Recent News & Updates

Vineet Laboratories (NSE:VINEETLAB) Seems To Be Using A Lot Of Debt

Jul 12
Vineet Laboratories (NSE:VINEETLAB) Seems To Be Using A Lot Of Debt

Recent updates

Vineet Laboratories (NSE:VINEETLAB) Seems To Be Using A Lot Of Debt

Jul 12
Vineet Laboratories (NSE:VINEETLAB) Seems To Be Using A Lot Of Debt

Earnings Working Against Vineet Laboratories Limited's (NSE:VINEETLAB) Share Price Following 25% Dive

Mar 07
Earnings Working Against Vineet Laboratories Limited's (NSE:VINEETLAB) Share Price Following 25% Dive

We Think Vineet Laboratories (NSE:VINEETLAB) Is Taking Some Risk With Its Debt

Feb 15
We Think Vineet Laboratories (NSE:VINEETLAB) Is Taking Some Risk With Its Debt

With EPS Growth And More, Vineet Laboratories (NSE:VINEETLAB) Makes An Interesting Case

Nov 14
With EPS Growth And More, Vineet Laboratories (NSE:VINEETLAB) Makes An Interesting Case

Shareholder Returns

VINEETLABIN PharmaceuticalsIN Market
7D-10.3%-0.6%-1.5%
1Y8.9%47.4%43.8%

Return vs Industry: VINEETLAB underperformed the Indian Pharmaceuticals industry which returned 47.4% over the past year.

Return vs Market: VINEETLAB underperformed the Indian Market which returned 43.8% over the past year.

Price Volatility

Is VINEETLAB's price volatile compared to industry and market?
VINEETLAB volatility
VINEETLAB Average Weekly Movement8.4%
Pharmaceuticals Industry Average Movement5.6%
Market Average Movement6.3%
10% most volatile stocks in IN Market9.7%
10% least volatile stocks in IN Market4.2%

Stable Share Price: VINEETLAB has not had significant price volatility in the past 3 months.

Volatility Over Time: VINEETLAB's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Indian stocks.

About the Company

FoundedEmployeesCEOWebsite
201672n/avineetlabs.co.in

Vineet Laboratories Limited engages in the research, development, manufacture, and sale of active pharmaceutical ingredients and fine chemicals in India. It offers intermediates of lopinavir, ritonavir, efavirenz, nadolol, glimepiride, celecoxib, olanine, and other API intermediates; and fine chemicals and reagents, such as isopropyl-beta-d-thiogalactopyranoside, 4-nitrophenyl phosphate disodium salt, 5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside, 5-acetyl thiophene-2-carboxilic acid, 4-chlorobutyryl chloride, n-butyl magnesium chloride, 3-furaldehyde, 3-bromofuran, n-butylnitrite, ethyldiazo acetate, phenylboronic acid, 6-aminouracil, and 1-methyl-imidazole-2-carboxaldehyde. The company was incorporated in 2016 and is based in Hyderabad, India.

Vineet Laboratories Limited Fundamentals Summary

How do Vineet Laboratories's earnings and revenue compare to its market cap?
VINEETLAB fundamental statistics
Market cap₹509.81m
Earnings (TTM)₹10.27m
Revenue (TTM)₹1.51b

49.6x

P/E Ratio

0.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VINEETLAB income statement (TTM)
Revenue₹1.51b
Cost of Revenue₹1.14b
Gross Profit₹366.72m
Other Expenses₹356.45m
Earnings₹10.27m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)1.11
Gross Margin24.35%
Net Profit Margin0.68%
Debt/Equity Ratio127.6%

How did VINEETLAB perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.